Treatment of systemic lupus erythematosus (SLE) with immunosuppressive drugs 1: An analysis of immunologic data.
D000328:Adult; D000368:Aged; D000974:Antibodies, Antinuclear / Q000032:analysis; D000917:Antibody Formation; D001323:Autoantibodies / Q000032:analysis; D001327:Autoimmune Diseases / Q000188:drug therapy; D001379:Azathioprine / Q000627:therapeutic use*; D003165:Complement System Proteins / Q000032:analysis; D004168:Diphtheria Toxoid; D005260:Female; D005455:Fluorescent Antibody Technique; D006801:Humans; D006968:Hypersensitivity, Delayed / Q000209:etiology; D007841:Latex Fixation Tests; D008180:Lupus Erythematosus, Systemic / Q000188:drug therapy*; D008297:Male; D008727:Methotrexate / Q000627:therapeutic use*; D008875:Middle Aged; D009578:Nitrobenzenes; D012482:Salmonella paratyphi A / Q000276:immunology; D013745:Tetanus Toxoid; D014374:Tuberculin Test; D014611:Vaccination; D005719:gamma-Globulins / Q000032:analysis
D000974:Antibodies, Antinuclear; D001323:Autoantibodies; D004168:Diphtheria Toxoid; D009578:Nitrobenzenes; D013745:Tetanus Toxoid; D005719:gamma-Globulins; D003165:Complement System Proteins; D001379:Azathioprine; D008727:Methotrexate